CurrentPriority Health MedicarePolicy 91451

Hyperhidrosis

Customize your policy alerts

Sign up for priority_health_medicare Policy 91451 alerts

Get alerted when Policy 91451 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy addresses medical necessity and coding for treatments of hyperhidrosis, including coverage criteria for intractable, disabling primary hyperhidrosis and exclusions for unproven or noncovered treatments.

Policy Summary

PayerPriority Health Medicare

PolicyHyperhidrosis

Policy CodePolicy 91451

Change TypeNon-material administrative update

Effective DateSep 1, 2026

Next Review DateN/A

Key ActionVerify whether prior authorization is required and submit documentation demonstrating medical necessity when required.

SourceLink

POLICY UPDATE CHANGES

Names of preferred botulinum toxin agents were deleted from Section I.A.

Details of benefits were deleted from Section I.B.

3Primary hyperhidrosis treatment categories with medical necessity criteria

6Not medically necessary or investigational treatment categories

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentPriority Health MedicarePolicy 91451

Hyperhidrosis

Customize your policy alerts

Sign up for priority_health_medicare Policy 91451 alerts

Get alerted when Policy 91451 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerPriority Health Medicare

PolicyHyperhidrosis

Policy CodePolicy 91451

Change TypeNon-material administrative update

Effective DateSep 1, 2026

Next Review DateN/A

Key ActionVerify whether prior authorization is required and submit documentation demonstrating medical necessity when required.

SourceLink

POLICY UPDATE CHANGES

Names of preferred botulinum toxin agents were deleted from Section I.A.

Details of benefits were deleted from Section I.B.

3Primary hyperhidrosis treatment categories with medical necessity criteria

6Not medically necessary or investigational treatment categories

10ICD-10 diagnosis codes supporting medical necessity

14CPT/HCPCS codes for not medically necessary indications

39Clinical and technology references cited

Medical Necessity and Exclusions

Medical necessity for primary hyperhidrosis

Treatment of intractable, disabling primary hyperhidrosis is medically necessary when at least one applicable treatment pathway below is met.

At least one applicable treatment pathway

Tumescent liposuction: Primary axillary hyperhidrosis is refractory to conventional medical treatment, including an attempt at both topical and systemic pharmacotherapy unless clinically contraindicated; the condition significantly interferes with the patient’s ability to perform age-appropriate activities of daily living; and the condition causes persistent or chronic cutaneous conditions.
Cutaneous conditions include skin maceration, dermatitis, fungal infections, and secondary microbial conditions.
Sympathectomy: Topical aluminum chloride or another extra-strength antiperspirant is ineffective or results in a severe rash; the patient is unresponsive or unable to tolerate prescribed pharmacotherapy; and there is skin maceration with secondary infections or significant functional impairment disrupting the individual’s professional and/or social life.
Examples of prescribed pharmacotherapy include anticholinergics, beta-blockers, or benzodiazepines.
Botulinum toxin treatment is used for intractable, disabling primary hyperhidrosis; coverage details, including preferred agents, are determined by the Drug Information page.

Exclusions and not medically necessary treatment

The following treatments are excluded or considered not medically necessary.

Any excluded or noncovered treatment applies

Compensatory hyperhidrosis: Surgical treatment of compensatory hyperhidrosis after open or endoscopic sympathectomy is not medically necessary.
Iontophoresis for primary hyperhidrosis: Treatment of primary hyperhidrosis with iontophoresis, including electrophoresis or the Drionic device, is experimental/investigational and not medically necessary.
Unproven treatments: Psychotherapy, hypnosis, laser treatment including subdermal Nd-YAG laser, microwave therapy, and percutaneous thoracic phenol sympathicolysis are not medically necessary because they have not been proven effective for hyperhidrosis.
Isolated plantar indication:

Surgical treatment of compensatory hyperhidrosis following open or endoscopic sympathectomy is considered not medically necessary.

Treatment of primary hyperhidrosis with iontophoresis, including electrophoresis or use of the Drionic device, is considered experimental/investigational and therefore not medically necessary.

Sympathectomy is considered not medically necessary when plantar hyperhidrosis is the only indication.

The following treatments are considered not medically necessary because they have not been proven effective for hyperhidrosis: psychotherapy, hypnosis, laser treatment (including subdermal Nd-YAG laser), microwave therapy, and percutaneous thoracic phenol sympathicolysis.

Diagnosis and Procedure Codes

ICD-10 Codes that may support medical necessityICD-10

L74.510	Primary focal hyperhidrosis, axilla
L74.511	Primary focal hyperhidrosis, face
L74.512	Primary focal hyperhidrosis, palms
L74.513	Primary focal hyperhidrosis, soles
L74.519	Primary focal hyperhidrosis, unspecified
L74.52	Secondary focal hyperhidrosis
R61	Generalized hyperhidrosis

CPT/HCPCS CodesmixedCovered

15877	Suction assisted lipectomy; trunk
15878	Suction assisted lipectomy; upper extremity
15879	Suction assisted lipectomy; lower extremity
32664	Thoracoscopy, surgical; with thoracic sympathectomy
64650	Chemodenervation of eccrine glands; both axillae
64653	Chemodenervation of eccrine glands; other area(s) (eg, scalp, face, neck), per day
64804	Sympathectomy, cervicothoracic
64809	Sympathectomy, thoracolumbar
J0585	Injection, onabotulinum toxin A, 1 unit; Botulinum toxin type A, per unit
J0586	Injection, abobotulinum toxin A, 5 units

1–10 of 13

1/2

Not Medically Necessary for indications in this policymixedNot Covered

17110	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions
17111	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions
64999	Unlisted procedure, nervous system (when billed for phenol sympathicolysis; Explanatory notes must accompany claims billed with unlisted codes)
90832	Psychotherapy, 30 minutes with patient and/or family member
90833	Psychotherapy, 30 minutes with patient and/or family member when performed with an evaluation and management service
90834	Psychotherapy, 45 minutes with patient and/or family member
90836	Psychotherapy, 45 minutes with patient and/or family member when performed with an evaluation and management service
90837	Psychotherapy, 60 minutes with patient and/or family member
90838	Psychotherapy, 60 minutes with patient and/or family member when performed with an evaluation and management service
90880	Hypnotherapy

1–10 of 18

1/2

Authorization, Documentation, and Treatment Requirements

Prior Authorization

Verify Prior Authorization

Prior authorization may be required for certain drugs, devices, services, and procedures. When required, submit a request demonstrating that the requested treatment is medically necessary; consult the Priority Health Provider Manual for additional requirements.

Prior Authorization

Individual Consideration Requires Approval

Experimental, investigational, or unproven treatment requires prior plan approval for individual consideration. Coverage determinations are made by a Priority Health medical director or clinical pharmacist.

An exception review may be available when the condition is terminal, chronic and life-threatening, or severely disabling with serious clinical deterioration.

Step Therapy

Clinical Background

Hyperhidrosis is sweating beyond what is necessary for thermal regulation. It may be primary or secondary. Primary hyperhidrosis, also called essential or idiopathic hyperhidrosis, is associated with overactivity of the sympathetic nervous system and commonly affects the palms, axillae, or soles. Secondary hyperhidrosis results from an underlying condition and usually affects the whole body; examples include Parkinson’s disease, hyperthyroidism, diabetes mellitus, hyperpituitarism, pyrexia, hypoglycemia, and menopause.

For secondary hyperhidrosis, treatment of the underlying condition should be attempted first. Severe, intractable, disabling primary hyperhidrosis may require topical or systemic therapy, botulinum toxin, or surgical treatment.

Key Terms

Hyperhidrosis

TermHyperhidrosis, or excessive sweating

DefinitionSweating beyond what is necessary to maintain thermal regulation.

Normal sweatingSweating is a natural phenomenon necessary for regulation of an individual’s body temperature.

Primary hyperhidrosis

DefinitionHyperhidrosis caused by an overactive sympathetic nervous system.

Also calledEssential or idiopathic hyperhidrosis.

Commonly affected areasPalms (hands), axillae (armpits), and plantar surfaces (feet).

Policy Summary

PayerPriority Health Medicare

PolicyHyperhidrosis

Policy CodePolicy 91451

Change TypeNon-material administrative update

Effective DateSep 1, 2026

Next Review DateN/A

Key ActionVerify whether prior authorization is required and submit documentation demonstrating medical necessity when required.

SourceLink

On This Page

Sympathectomy is not medically necessary when plantar hyperhidrosis is the only indication.

Document Failure of Topical and Systemic Therapy

Before requesting tumescent liposuction for primary axillary hyperhidrosis, document that the condition is refractory to conventional medical treatment, including an attempt at both topical and systemic pharmacotherapy unless clinically contraindicated.

The treatment-specific medical-necessity criteria must also be met: significant interference with age-appropriate activities of daily living and persistent or chronic cutaneous conditions such as skin maceration, dermatitis, fungal infections, or secondary microbial conditions.

Unsupported block type: step_therapy

Unsupported block type: documentation

Documentation Required

Document Condition and Treatment Details

Document that the patient has intractable, disabling primary hyperhidrosis and include the condition-specific findings and treatment criteria supporting the requested intervention.

For tumescent liposuction, identify primary axillary disease, refractory conventional treatment, functional interference, and persistent or chronic cutaneous complications.
For sympathectomy, document failed or intolerable topical and pharmacologic therapy, plus skin maceration with secondary infections or significant functional impairment disrupting professional or social life.

Unsupported block type: billing_rule

Denial Risk

Compensatory Hyperhidrosis Surgery Is Not Medically Necessary

Do not request or bill surgical treatment of compensatory hyperhidrosis as medically necessary when it follows open or endoscopic sympathectomy.

Denial Risk

Iontophoresis Is Investigational

Iontophoresis for primary hyperhidrosis, including electrophoresis, Drionic devices, and home iontophoresis units, is experimental or investigational and is not medically necessary.

This includes iontophoresis services and home units, including CPT 97033 and HCPCS E1399.

Denial Risk

Unproven Treatments and Isolated Plantar Indication

The following treatments are not medically necessary because they have not been proven effective for this indication. Sympathectomy is also not medically necessary when plantar hyperhidrosis is the only indication.

Psychotherapy
Hypnosis
Laser treatment, including subdermal Nd-YAG laser
Microwave therapy
Percutaneous thoracic phenol sympathicolysis
Sympathectomy when plantar hyperhidrosis is the sole indication

Documentation Required

Apply Tumescent Liposuction Criteria

Tumescent liposuction may be medically necessary for primary axillary hyperhidrosis only when the condition is refractory to conventional medical treatment, including attempted topical and systemic pharmacotherapy unless clinically contraindicated, and the required functional and cutaneous criteria are documented.

The condition must significantly interfere with the patient's ability to perform age-appropriate activities of daily living.
The condition must cause persistent or chronic cutaneous conditions, such as skin maceration, dermatitis, fungal infections, or secondary microbial conditions.

Step Therapy

Apply Sympathectomy Criteria

Sympathectomy is medically necessary only when all required criteria are met: topical aluminum chloride or another extra-strength antiperspirant is ineffective or causes a severe rash; prescribed pharmacotherapy such as anticholinergics, beta-blockers, or benzodiazepines is ineffective or not tolerated; and the patient has skin maceration with secondary infections or significant functional impairment disrupting professional or social life.

Document the specific failed or intolerable treatments and the resulting clinical or functional impairment.

Secondary hyperhidrosis

DefinitionHyperhidrosis resulting from an underlying condition.

Underlying conditionsParkinson’s disease, hyperthyroidism, diabetes mellitus, hyperpituitarism, pyrexia, hypoglycemia, or menopause.

Typical distributionUsually affects the whole body.

Compensatory hyperhidrosis

DefinitionIncreased sweating in other parts of the body.

Relationship to sympathectomyIt is described as the most common side effect of open or endoscopic sympathectomy.

Clinical contextThe condition occurs after open or endoscopic sympathectomy and involves sweating at sites other than those primarily affected.